Core Viewpoint - The company announced the completion of the first patient dosing in a Phase II clinical trial evaluating the efficacy and safety of Tinengotinib in combination with other therapies for advanced hepatocellular carcinoma [1] Group 1: Clinical Trial Details - The trial is an open-label, multicenter Phase II study conducted in China [1] - It aims to assess the safety and efficacy of Tinengotinib combined with Kantonib (PD-1/CTLA-4) and Yidafang (PD-1/VEGF) in treating advanced hepatocellular carcinoma [1] - The primary target population includes patients who have not previously received systemic anti-tumor treatment for hepatocellular carcinoma or those who have failed standard treatment [1] Group 2: Collaboration - The company has established a collaboration agreement with Kanton Biotechnology to jointly develop clinical combination therapies in the field of hepatocellular carcinoma [1]
药捷安康-B(02617)：替恩戈替尼联用康方生物开坦尼®(卡度尼利，PD-1/CTLA-4)╱ 依达方®(依沃西，PD-1/VEGF)的II期临床试验...